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Summary: While porphyria cutanea tarda and porphyria variegata are independent diseases, we report on seven
rare cases with a coincidence of these two different porphyrias in one Individuum.
The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea
tarda and a facultative one in porphyria variegata. Additionally, five patients had also experienced episodes of acute
abdominal pain, which were in three cases accompanied by neurological symptoms, thus offering evidence for an
acute hepatic porphyria, such as porphyria variegata.
Determination of urinary porphyrin metabolites revealed a porphyria cutanea tarda-like excretion pattern with an
elevation of uroporphyrin (mean 1134 nmol/24h, range 563—4052, normal < 30) and heptacarboxyporphyrin
(mean 389 nmol/24h, range 64—830, normal ^4). In all patients, however, urinary coproporphyrin was also
increased, reaching levels too high for porphyria cutanea tarda but typical for porphyria variegata (mean 1788 nmol/
24 h, range 142—4168, normal ^ 120). Fecal porphyrin excretion also resembled the variegate-type with a high
concentration especially of protoporphyrin (mean 628 nmol/g dry weight, range 401 — 1018, normal ^  151), accom-
panied by an increase of coproporphyrin (mean 194 nmol/g dry weight, range 75—409, normal < 37). The urinary
porphyrin precursors 5-aminolaevulinic acid and porphobilinogen were markedly elevated only in one patient, who
was in an acute porphyric phase at the time of investigation. The activity of uroporphyrinogen decarboxylase in
erythrocytes was considerably decreased in six of our cases (33—64%) and slightly diminished in the other one
(83% of normal activity).
Those metabolic excretion profiles, supplemented by the cutanea tarda-associated uroporphyrinogen decarboxylase
deficiency, reflect ari intermediate pattern with characteristics of both porphyria cutanea tarda and variegata, as was
confirmed by comparison with 15 cases of porphyria variegata and 10 cases of porphyria cutanea tarda.
Introduction be toxically induced by polyhalogenated hydrocarbons
_ , . · , , ,. ,. , like hexachlorobenzene (1). Porphyria variegata, anPorphyrias are mainly hereditary diseases, each one re-
flecting a partial genetic defect of one of the enzymes
along the heme biosynthetic pathway (1,2). ') Presented in part at the "International Meeting on Porphyrin
Metabolism and Iron Metabolism", April 30-May 4, 1992, Papen-
Porphyria cutanea tarda or chronic hepatic porphyria, dal, The Netherlands, and at the symposion "Photobiology and
resulting from uroporphyrinoeen decarboxvlase3) defi- Phototherapy", VII International Congress of Dermatology, New
. ., ! . * " , · / · j . . Delhi, India, February 26-March 2, 1994.
ciency, is the most frequent porphyna (estimated mci- 2, ^
 study was Supp0rted by the Hans-Fischer-Gesellschaft, Mu-
dence in Germany ~ 20-50 : 100000) (2) and can also nich.
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Tab. l Clinical symptoms in dual porphyria of variegata and cutanea tarda.
Patient Sex Year of
1 *_^|birth
Age [a] at Porphyria variegata
diagnosis
Chronic hepatic porphyria
abdominal cardiovascular neurologic cutaneous liver affection
1
2
3
4
5
6
7
ο
ρ
?$
9
δ
<S
1975
1963
1955
1950
1948
1954
1951
12
21
34
38
31
30
32
+ n.k.*
+ ' 0
0 0
0 n.k.
+ +
+ 0
+ 0
n.k. +
-h +
0 +
n.k. +
+ +
0 +
+ +
n.k.
+
+
' n.k.
+
0
0
* n. k. = not known
acute hepatic porphyria with protoporphyrinogen oxi-
dase3) defect, has a lower incidence of approximately
1 : 100000 in Germany (2).
Hereditary porphyrias are rare diseases by themselves;
even more rare are forms of dual porphyria, i. e. the co-
existence of two different gene defects in one indivi-
duum. We present here seven cases of a coinciding por-
phyria variegata and porphyria cutanea tarda.
Patients and Methods
The clinical data of our patients are compiled in table 1. Two of
them came from India (1 and 2), the other five were Germans.
Apart from two brothers (6 and 7) they were not related.
Urinary porphyrin precursors 5-aminolaevulinic acid and porpho-
bilinogen were determined by ion-exchange chromatography and
absorption spectrophotometry, urinary and fecal porphyrins by high
performance thin-layer chromatography in combination with ab-
sorption spectrophotometry and spectrofluorometry (3). Copropor-
phyrin isomers were analysed by high performance liquid chroma-
tography and absorption photometry (4). Uroporphyrinogen decar-
boxylase was measured in red cell lysates according to the method
previously described (5).
Statistical evaluation was performed by Wilcoxon's, Mann's and
Whitney^ U-test.
Results
Clinical evaluation
All patients (tab. 1) revealed a cutaneous photosensitiv-
ity of varying degrees, the most frequent symptom being
an increased fragility of the skin with superficial bullae
and erosions, which subsided leaving small scars (1-5),
or with erythema (6, 7). Hypertrichosis and hyperpig-
mentation in the face were observed in patient 2, while
patient 6 also complained about pruritus.
3) Enzymes:
5-Aminolaevulinate synthase (EC 2.3.1.37)
Protoporphyrinogen oxidase (EC 1.3.3.4)
Uroporphyrinogen decarboxylase (EC 4.1.1.37)
However, signs of acute porphyria, namely recurring ep-
isodes of abdominal pain often accompanied by nausea
and vomiting, were the predominating symptoms in pa-
tients 1, 2, 5 and 7, thus directing diagnostic suspicion
towards the manifestation of an acute hepatic porphyria.
Neurological symptoms were epileptic seizures and un-
consciousness (patient 2), hypesthesia (2 and 5), slight
paresis (7) and psychic symptoms (depression in patient
5 and change of personality in patient 7).
In patients 3,4 and 6, the cutaneous symptoms prevailed
with abdominal symptoms being discrete (6) or absent
(3 and 4). Therefore, these patients were admitted under
the suspicion of chronic hepatic porphyria, i.e. por-
phyria cutanea tarda. Liver affection, a characteristic
finding in porphyria cutanea tarda (6, 7), was found in
patients 2 (increased urinary coproporphyrin I propor^
tion, see below), 3 (increased aminotrarisferases) and 5
(increased urinary coproporphyrin I proportion, see be-
low; liver biopsy: intrahepatic cholestasis, necrosis and
fatty degeneration of single hepatocytes).
Family studies could not be performed apart from the
investigation of a sister of the two brothers 6 and 7. The
sister, born in 1943, suffered from porphyria cutanea
tarda; histologically, a chronic hepatitis with moderate
fibrosis was determined.
Pathobiochemical evaluation
Urinary and fecal porphyrin metabolites of the patients
were investigated and compared to 10 cases of porphyria
cutanea tarda and 15 cases of porphyria variegata (figs.
1 —3 and tab.2). The metabolite excretion profiles of our
seven patients revealed an intermediate pattern with
characteristics of both porphyria variegata and eutanea
tarda.
The increase of urinary coproporphyrin, in one case ac-
companied by a distinct elevation of the porphyrin pre·^
cursors S^aminolaevulinic acid and porphobilinogen,
and the fecal porphyrin pattern with distinctly elevated
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excretion rates especially of protoporphyrin and also of
coproporphyrin, offer a constellation characteristic for
porphyria variegata. However, the high values of urinary
uroporphyrin and heptacarboxyporphyrin are typically
Λ
5-Aminolaevulinate Porphobilinogen
Fig. 1 Excretion of urinary porphyrin precursors: dual poφhyria
versus cutanea tarda and variegata.
D normal range, m porphyria variegata, B dual porphyria, Offl por-
phyria cutanea tarda
4000
Uro- 7-Carboxy- Copro- Total
porphyrin poφhyrin poφhyrin poφhyrins
Fig. 2 Excretion of urinary porphyrins: dual porphyria versus cu-
tanea tarda and variegata.
D normal range, M porphyria variegata, II dual porphyria, d por-
phyria cutanea tarda
Coproporphyrin Protoporphyrin
Fig. 3 Excretion of fecal porphyrins: dual porphyria versus cuta-
nea tarda and variegata.
D normal range, g porphyria variegata, β dual porphyria, QQ) por-
phyria cutanea tarda
seen in porphyria cutanea tarda (tab. 3), as is the reduc-
tion of erythrocyte uroporphyrinogen decarboxylase ac-
tivity (tab. 4). In six of our patients uroporphyrinogen
decarboxylase activity ranged between 33 and 66% of
healthy controls, only one (patient 7) reached the near
normal level (83%). Red blood cells contained normal
amounts of protoporphyrin (data not shown).
Urinary coproporphyrin isomers I and III were deter-
mined in three cases; two of them (patient 2 and 5)
showed an increased proportion of isomer I (50% and
55%, respectively, normal ^ 31%), while in patient 7
isomer III dominated both in urine (84%, upper normal
value 83%) and feces (78%, upper normal value 40%)
in accordance with porphyria variegata (4, 8). Patient 2
also excreted an elevated fecal coproporphyrin III pro-
portion of 57%.
Discussion
Dual porphyrias are rare and have so far been reported
as combinations of acute intermittent porphyria and por-
phyria variegata (9), acute intermittent porphyria and
porphyria cutanea tarda (10), as well as hereditary
coproporphyria and congenital erythropoietic porphyria
(11). We present seven cases of a coinciding porphyria
variegata and porphyria cutanea tarda, as has first been
described by Day and coworkers in the South African
population (12). Variegate porphyria, also known as
"South Africa genetic porphyria", has a comparatively
high incidence in the white South African population of
approximately 250 : 100000 (13). Elsewhere, variegate
occurs far less frequently (2). To our knowledge, only
one single case report of a possible coexisting porphyria
variegata and cutanea tarda has been published since in
1987 (14). We present the first case collection of this
dual porphyria outside Africa.
The extraordinary urinary and fecal porphyrin patterns
in our seven patients reveal characteristics both of por-
phyria cutanea tarda and variegata. Urinary copropor-
phyrin as well as fecal protoporphyrin and coproporphy-
rin excretion did not significantly differ from the pattern
of 15 variegate cases (tab. 3); the same was found for
urinary porphyrin precursors (5-aminolaevulinic acid
and porphobilinogen), which were consistent with latent
(n = 6) or overt (n = 1) variegata, thus offering a me-
tabolite profile compatible with protoporphyrinogen oxi-
dase deficiency (1, 15). With most excretion parameters
indicating porphyria variegata, urinary uroporphyrin and
heptacarboxyporphyrin levels were found to be excep-
tionally high for porphyria variegata, all the more for
latent variegate, directing suspicion more towards por-
phyria cutanea tarda (1, 16). Indeed, statistical evalua-
tion (tab. 3) gave no significant difference between our
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Tab. 2 Excretion of urinary and fecal porphyrin metabolites
tarda and variegata.
dual porphyria in comparison to cutanea
Porphyria
variegata
(n = 15)
Porphyria
cutanea tarda
(n = 10)
Dual
porphyria
(n = 7)
Reference
range
Urine
5-Amino-
laevulinate
[μιηοΙ/24 h]
167*
(13-487)**
21
(Π-33)
84*
(19-196)
2-50
Porpho-
bilinogen
[μιηοΙ/24 h]
141
(1.5-639)
2.5
(1-4)
19
(2-101)
0.5-8
Uro-
porphyrin
[nmol/24 h]
586
(16-3408)
1669
(235-4043)
1134
(563-4052)
4-30
Hepta-
carboxy-
porphyrin
[nmol/24 h]
47
(3-188)
644
(166-1518)
389
(64-830)
0-4
Copro-
porphyrin
[nmol/24 h]
1437
(148-2930)
273
(98-417)
1788
(142-4168)
21-120
Total
porphyrins
[nmol/24 h]
2433
(176-6009)
2833
(586-6263)
4031
(1221-9972)
25-165
Feces
Copro-
porphyrin
[nmpl/g]
284
(28-714)
62
(6-176)
194
(75-409)
5-37
Proto-
porphyrin
[nmol/g]
923
(123-2293)
57
(21-151)
628
(401-1018)
21-151
"mean range
Tab. 3 Statistical, evaluation of excretion patterns by Wikoxon's, Mann's and Whitney's
U-test: dual porphyria versus cutanea tarda and variegata.
Dual porphyria vs.
porphyria cutanea tarda
Dual porphyria vs.
porphyria variegata
Urinary
Σ (5-Amino-
laevulinate,
porphobilinogen)
s.
(p < 0.005)
n.s.
(P>0.1)
Uro-
porphyrin
n.s.
(p > 0.05)
s.
(p<0.01)
7-Carboxy-
poφhyrin
n.s.
(p > 0.05)
s.
(p < 0.001)
Copro-
porphyrin
s.
(p< 0.001)
n.s.
(P > 0.2)
Fecal
Copro-
porphyrin
s.
(p < 0.005)
n.s.
(p > 0.2)
Proto-
porphyrin
s.
(p< 0.001)
n.s.
(P>0.1)
s. = significantly different (p < 0.05); n. s. = not significantly different (p > 0.05).
patients and a porphyria cutanea tarda control group re-
garding uro- and heptacarboxyporphyrin.
To exclude the possibility that the high uro- and hepta-
carboxyporphyrin levels were indirectly caused by the
protoporphyrinogen oxidase defect, we investigated
erythrocyte uroporphyrinogen decarboxylase activity,
which was markedly reduced in six and moderately di-
minished in one patient. This erythrocyte enzyme defi-
Tab. 4 Enzyme activity in red blood cells.
Activity of
uroporphyrinogen decarboxylase
[in % of healthy controls]
Dual porphyria
n = 7
Porphyria cutanea tarda
n = 10
50*
62
(33-83)**
. (50-76)
mean range
ciency is probably of no or minor significance for the
biochemical and clinical pathogenesis of porphyria cuta-
nea tarda. However, it may serve as a marker for genetic
or type II porphyria cutanea tarda, which is charac-
terized by an approximate 50% reduction of uroporphyr^
inogen decarboxylase activity in all tissues including
erythrocytes and liver. In sporadic or type I porphyria
cutanea tarda the enzyme defect is restricted to the liver
(17). Although the classification of porphyria cutanea
tarda may be more complex (17, 18), it can be assumed
that uroporphyrinogen decarboxylase affection in most
of our patients results from genetic factors, only for pa-
tient 7 (82% uroporphyrinogen decarboxylase activity in
red blood cells) might the possibility of a type I por-
phyria cutanea tarda be considered. But even in this case
genetic factors cannot be completely ruled out, as his
brother (patient 6) and sister also suffered from por-
phyria cutanea tarda. The affection of hepatic uropor-
phyrinogen decarboxylase is thought to be the deciding
factor for initiation of the disease process; liver uro-
Eur J Clin Chem Clin Biochem 1995; 33 (No 7)
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porphyrinogen decarboxylase is also susceptible to toxic
influences (1). As possible triggering factors for por-
phyria cutanea tarda, liver affection was found in three
patients (2, 3 and 5); two of them (3 and 5) had been
applying oral contraceptives.
Urinary coproporphyrin isomers I and III were analysed
in three patients. An increased proportion of isomer I
could be detected in two cases (2 and 5) as typical for
cholestatic liver disease (4, 8), while patient 7 revealed
a high level of urinary coproporphyrin III. This is char-
acteristically found in acute hepatic porphyrias (4, 8);
more sensitive than in urine, where coproporphyrin III
is even under normal conditions the dominating isomer
(normal 69-83% copropoiphyrin III, 17-31% copro-
porphyrin I), an increase of isomer III can be proved in
feces. In this specimen, healthy individuals excrete
lower proportions of coproporphyrin III, ranging only
between 25 and 40%, than in urine. An increase of the
fecal coproporphyrin III proportion may be used as indi-
cator for an acute hepatic porphyria, even when in a
latent phase (4, 19). The determination of fecal copro-
porphyrin III could be performed in two of our patients
(2 and 7); both of them revealed an elevated copropor-
phyrin III proportion (57%; 78%).
With the exception of higher urinary coproporphyrin
values in our group, the porphyrin metabolite pat-
tern of the seven patients presented here resembles
the one which Day and coworkers (12) found in
25 South Africans and recognized as coexistent por-
phyria variegata and cutanea tarda. Some years later,
Sturrock and coworkers reinvestigated 10 of Day's
patients and demonstrated the postulated enzyme de-
fects of protoporphyrinogen oxidase (decreased by
45% in lymphocytes) and of uroporphyrinogen decar-
boxylase (decreased by 27% in lymphocytes and
erythrocytes) (20).
Both genetic porphyria cutanea tarda and porphyria va-
riegata follow an autosomal dominant trait of inheri-
tance, though with a low clinical penetrance. The genes
encoding uroporphyrinogen decarboxylase and proto-
porphyrinogen oxidase seem to be localized on different
chromosomes: chromosome 1 for uroporphyrinogen de-
carboxylase and chromosome 14 for protoporphyrino-
gen oxidase (21). Although family investigations were
not possible in this study, we suppose that our cases of
dual porphyria result from the incidential genetic trans-
mission of two independently occurring gene defects,
most likely one from each parent. Therefore, with each
parent being heterozygote for either porphyria cutanea
tarda or porphyria variegata, their children had a 25%
chance each of:
- becoming double heterozygotes for porphyria cuta-
nea tarda and porphyria variegata,
— becoming heterozygote for porphyria cutanea tarda,
— becoming heterozygote for porphyria variegata,
— becoming not genetically predisposed.
An indication for this hypothesis could be seen in the
sister of brothers 6 and 7, who suffered from porphyria
cutanea tarda with no indication of variegata.
Another point of interest would be the question whether
there was a special effect of this dual enzyme deficiency
on the expression of porphyria cutanea tarda or varie-
gata. Porphyria cutanea tarda is an accumulation disease
of higher carboxylated porphyrins, mostly uro- and hep-
tacarboxyporphyrin, which cause the typical photoder-
matosis when deposited in the skin. In contrast, por-
phyria variegata is a regulatory disorder of porphyrin
metabolism caused by the excessive, uncontrolled induc-
tion of 5-aminolaevulinate synthase, the first and rate-
limiting enzyme of heme biosynthesis, with the conse-
quence of an increased supply of substrates for the en-
zymes along the heme synthetic pathway (16). This sur-
plus of substrate might overtax a genetically afflicted
uroporphyrinogen decarboxylase, thus increasing the
dermal porphyrin deposition, which can be found in
about one third of porphyria variegata cases, by addi-
tional amounts of (mainly) uro- and heptacarboxypor-
phyrin. It can be assumed that patients with a dual por-
phyria of cutanea tarda and variegata might at least be
more susceptible for the development of photodermato-
sis. More investigations will be necessary to elucidate
this question.
While in porphyria cutanea tarda the mobilization and
successive renal elimination of accumulated liver por-
phyrins by low-dose chloroquine treatment has become
a successful therapy (7, 22), in the case of dual variegate
— cutanea tarda it should be considered that chloroquine
sometimes induces acute porphyria manifestations (23).
Therefore, chloroquine should either be omitted in these
cases or, if the variegate is in a latent and stable phase
(constantly normal urinary 5-aminolaevulinic acid and
porphobilinogen levels), be applied under continuous
clinical and pathobiochemical monitoring of urinary 5-
aminolaevulinic acid, porphobilinogen and porphyrin
excretion.
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